Another poster made a comment about whether or not the Intel lawsuit will create the opportunity for HDC to benefit from other infringing parties who might now be more inclined to come forward. Obviously, time will tell, and perhaps the results of the suit might dictate such a willingness.
Either way, these thoughts reminded me of some statements that our friends at Neogenomics made way back in 2012, and which were incorporated into that year's May 10-Q (see below). Certainly, I have no idea as to whether or not Neo actually advanced this, but their own words suggested that they, at the time, fully intended to use SVM-RFE. Perhaps we have finally reached a point where HDC and its shareholders start to realize some well-deserved and long-overdue rewards.
"We are also focused on innovation because we are committed to being a leader in oncology testing. With the recent advances in genomics, proteomics and digital pathology, frequently large amounts of data are generated and managing this data is difficult without the aid of computer-based algorithms and pattern recognition. We believe that the best system for pattern recognition and data analysis is a technology known as Support Vector Machine or “SVM”, especially when combined with a technology called Recursive Feature Elimination or “RFE”.
Health Discovery Corporation has an extensive array of pending and issued patents surrounding SVM and RFE technology. By licensing this technology and combining the expertise that already existed at Health Discovery Corp with our expertise in genomics, proteomics and digital imaging, we believe we are well-positioned to begin developing innovative and proprietary new products.
Our goal is to develop new assays to help our physicians better manage their patients and to enable them to practice evidence-based medicine tailored specifically for each of their patients. High priority will be given to the development of better tests for the diagnosis and prediction of clinical behavior in prostate cancer, pancreatic cancer, breast cancer and leukemia/lymphoma.
We intend to combine and analyze data from genomics, proteomics and digital imaging using SVM-RFE techniques to develop practical, cost-effective and reliable new assays. Using this technology, we believe we will be able to offer a whole line of advanced tests that will help physicians better manage the treatment options for cancer patients."
